Eli Lilly Agrees To Reduce And Cap Insulin Prices

The New York Times reports:

The drug maker Eli Lilly and Company said on Wednesday that it would significantly reduce the prices of several of its lifesaving insulin products that are used by diabetes patients and whose prices Lilly has repeatedly increased in the past.

Lilly also said it would cap at $35 a month what patients pay out of pocket for the drugmaker’s insulin products.

Insulin, which is usually taken daily, has grown increasingly expensive in recent years despite the introduction of new competition. Many diabetes patients ration their medicines or discontinue them because of the cost.

Huge news.

Last year, we capped insulin prices for seniors on Medicare, but there was more work to do.

I called on Congress – and manufacturers – to lower insulin prices for everyone else.

Today, Eli Lilly is heeding my call. Others should follow. https://t.co/Kv57KFATe9

— President Biden (@POTUS) March 1, 2023

Read the full article.

BREAKING: This change now puts the drugmaker in line with a provision Democrats passed for seniors in the Inflation Reduction Act.

Reminder: Every single Republican in Congress voted AGAINST it. https://t.co/Pu5ZaRGJUU

— CAP Action (@CAPAction) March 1, 2023